Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.

Novo's lawsuit comes less than one week after Hims & Hers announced plans to sell a compounded version of Novo's weight-loss ...

Telehealth company will offer oral and injectable versions of the GLP-1 drug ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

Novo Nordisk is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company's patents, and is seeking to recover damages. The move escalates the ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

Add Yahoo as a preferred source to see more of our stories on Google. Novo Nordisk files suit against telehealth provider Hims & Hers, alleging unauthorized versions of Ozempic and Wegovy. The case ...

Hims & Hers reversed course on its launch of a cheaper, copycat version of Novo Nordisk’s GLP-1 weight loss pill amid legal action. In a Feb. 7 social media post, the San Francisco-based telehealth ...

Novo Nordisk is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker's new Wegovy obesity pill and injections in the U.S. Novo is asking the ...